Ferucarbotran of Iron oxide

Ferucarbotran (carboxy dextran-coated iron oxide nanoparticles, SHU 555 C, Resovist, Schering AG) is a contrast agent that consists of iron oxide microparticles coated with carboxy dextran. After intravenous injection, it is sequestered by the reticuloendothelial system, mostly in the liver and spleen. MRI iron oxide causes loss of signal intensity, especially on T1 and T2 weighted images. The contrast between the lesions and the surrounding tissues increases due to the loss of signal in the healthy tissues. Feruglose: Feruglose (NC100150, Clariscan, Nycomed, Oslo, Norway) has been given to 18 healthy men in doses of 2, 3, and 4 mg/kg. There were no significant adverse effects during or after the scans. However, NC100150 interferes with iron metabolism since iron is incorporated into the body after biodegradation. NC100150 shows promise for myocardial perfusion analysis. Animal studies have also suggested a role for NC100150 in detecting and localizing intra-abdominal bleeding. Ferumoxtran: Ferumoxtran-10 (Combidex, Advanced Magnetics, Cambridge, MA) is an ultrasmall superparamagnetic iron oxide agent. It targets the reticuloendothelial system but also functions as a blood-pool agent. In a phase 2 study of 104 patients with focal liver or spleen pathology who underwent MRI with ferumoxtran-10 (0.8, 1.1, and 1.7 mg of iron per kg), 15% reported a total of 33 adverse events, most commonly dyspnea (3.8%), chest pain (2.9%), and rashes (2.9%). There were no serious adverse events during the 48-hour observation period and no changes in vital signs, physical examination, or laboratory parameters. The authors concluded that ferumoxtran-10 is safe and well-tolerated. If you are looking for high quality, high purity and cost-effective Iron oxide, or if you require the latest price of Iron oxide, please feel free to email contact mis-asia.